Simergent Secures $2.835M Seed Funding to Advance Home Hemodialysis Device Archimedes, Cutting Patient Costs by 85%

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on April 25, U.S. local time, medical device company Simergent completed a $2.835 million seed funding round. The proceeds from this round will be used to advance the research and development of Archimedes, a hemodialysis device designed to help patients with renal dysfunction perform hemodialysis at home.

It is reported that this round of financing was led by i2E.

Simergent, a medical device company founded in 2014 and headquartered in Illinois, USA, is developing the Archimedes home automated peritoneal dialysis system under the leadership of CEO Steve Lindo.

The kidneys are organs responsible for transporting water and eliminating toxins in the human body. When kidney function is impaired, excess water and toxic substances cannot be effectively cleared from the body. Kidney dysfunction not only leads to edema and physical debility but also causes various health problems.

Hemodialysis is a blood purification method that, in clinical medicine, refers to the removal of certain impurities from the blood through a semipermeable membrane. It is commonly used for patients with acute renal failure, acute drug poisoning, or rejection reactions following kidney transplantation. Patients undergoing hemodialysis need to visit the hospital regularly for dialysis sessions to eliminate excess substances from the body and maintain health.

Archimedes is a hemodialysis device that enables patients to complete dialysis treatments at home. It offers the following advantages: (1) Ease of use: After purchasing the device, the company provides professional staff to help patients understand the operational procedures; Archimedes features visualized control buttons, making it easier for patients to learn how to use it. (2) Affordability: Compared with traditional dialysis, patients can save nearly 85% of the costs, thereby alleviating the financial burden on ordinary households. (3) Convenience: Patients can perform dialysis at home at any time, eliminating the need to wait in line at hospitals every week.

Steve Lindo, Founder and CEO of Simergent, stated, “Technology has benefited numerous fields, and we aim to harness its power to help patients optimize the consultation process. There are many patients worldwide suffering from the burdens of dialysis, while hospital dialysis equipment is limited. Enabling patients to undergo hemodialysis at home would not only free up more medical resources but also make it more convenient for patients to receive treatment.”

i2E CEO Scott Meacham stated, “We are highly enthusiastic about our collaboration with Simergent to achieve breakthrough advancements in the field of hemodialysis. The hemodialysis market holds significant growth potential; however, due to the complexity of equipment operation, patients are currently limited to receiving treatment at hospitals. We aim to enable patients to undergo hemodialysis at home, thereby reducing their out-of-pocket medical expenses.”

i2E, established in 1997, is a venture capital firm headquartered in Oklahoma, USA, specializing in early-stage investments in biotechnology startups. Currently, the firm’s primary investment focus is geographically concentrated in Oklahoma.

(Compiled by Liu Yujing)